cross-referenced news and research resources about

 Merck logo
images:  google   yahoo YouTube

updated Tue. March 20, 2018

After touching a high of Rs.1519.00 and dropping as low as Rs.1497.05 through the day, one stock of Merck Ltd. was observed to be priced at Rs.1505. A total of 2,929 stocks were observed to be traded with the volume weighted average price being Rs.1505.76. The bid price was Rs.1505.00 for 7 stocks ...
The most recent earnings release Merck Limited's (NSEI:Merck) announced in December 2017 confirmed that the business gained from a robust tailwind, eventuating to a double-digit earnings growth of 23.74%. Below, I've laid out key numbers on how market analysts predict Merck's earnings growth ...

Merck & Co., Inc. (MRK) is an interesting player in the Healthcare space, with a focus on Drug Manufacturers - Major. The stock has been active on the tape, currently trading at $55.67, up from yesterday's close by 0.76%. Given the stock's recent action, it seemed like a good time to take a closer look at the ...
For Merck & Co. Inc, irrespective of whether the earnings move was up or down, if we waited two calendar days after the stock move, and then sold a one-month out of the money put spread, the results were simply staggering. We use two-days to allow the stock to fully reach equilibrium post earnings. Intelligent
Shares of Merck & Company Inc. (new) (MRK) ended the trading day Monday at $54.63, representing a move of -1.87%, or $1.04 per share, on volume of 11.19 million shares. Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic ...
Merck & Co. has entered a global strategic oncology collaboration with Eisai to jointly develop and commercialize Lenvima (lenvatinib mesylate) as a monotherapy and in combination with Merck's anti-cancer biologic, Keytruda (pembrolizumab), for treating multiple cancer types, Merck announced in a ...

n a setback to the pharmaceutical industry, the Massachusetts Supreme Judicial Court decided that consumers who claim harm from a generic medicine can sue brand-name drug makers for intentionally failing to update warnings that generic companies are obligated to place on product labeling. pharma
The U.S. Food and Drug Administration will be giving priority review to Merck's Keytruda (pembrolizumab) as a treatment for women whose advanced cervical cancer progressed during or after chemotherapy. Priority review means the agency will decide whether to approve the Biologics License ... pharma
Let's put Merck & Co., Inc.MRK stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing ... We should also point out that Merck & Co. has a forward PE ratio (price relative to this year's earnings) of just 13.1, so it is fair to say that a slightly more ... pharma
This week, 56 outstanding veterinary students from around the world received scholarships from Merck Animal Health, in partnership with the American Veterinary Medical Foundation (AVMF). Through the Merck Animal Health Veterinary Student Scholarship Program, the selected second-and third-year ... pharma
In 4Q17, Merck (MRK) generated revenues of $186 million from the sales of Remicade, which reflected a ~31% decline on a YoY (year-over-year) basis and 13% decline on a QoQ (quarter-over-quarter) basis. In fiscal 2017, Merck generated revenues of $837 million from the sales of Simponi, compared ... pharma
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. pharma
So, we'll get started with the Merck session. We're delighted to have Merck here, which company management went through tremendous efforts to be with us here due to weather and elevators and all kinds of stuff. So, we deeply appreciate you're being with us. Representing the company is Roger Dansey, ... pharma
Frazier, the grandson of a man born into slavery, was the first of a series of chief executives to distance himself from the president. "I feel a responsibility to take a stand against extremism," he wrote on Merck's Twitter account at the time. In a recent interview with The New York Times, Frazier elaborated for ... CEO
Now that we have full year numbers for Merck (NYSE:MRK), we can go over the company's long term financials to see if the healthcare company makes a sound long term investment. Keytruda from the immuno oncology segment is driving the company forward and fending off encroaching generic ... CEO
Shares of Merck & Company Inc. (new) (MRK) ended the trading day Thursday at $54.57, representing a move of 0.04%, or $0.02 per share, on volume of 10.48 million shares. Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic ... CEO
WHEN Ken Frazier, chief executive of Merck, an American pharmaceutical giant, started his job in 2011, he had a hard decision to make. The firm had promising new drugs—such as Januvia, for diabetes, and Gardasil, a vaccine against cervical cancer. But the pharma industry was struggling with dismal ... CEO

Merck started developing ERK inhibitors in 2013 to plug a gap in the treatment of melanomas and other cancers with BRAF mutations. Targeted treatments for these cancers are available, but patients often become resistant and their cancer returns. The candidate in question, MK-8353, targets downstream ... CEO
Viralytics said Cavatak was particularly effective when used in conjunction with Merck's immune-boosting drug Keytruda. The Australian firm's CEO Malcolm McColl said the drug was actually a virus that had been found to kill cancer cells. Trials on more than 250 patients in the US had shown tumour ... CEO
In a much-publicized surprise at the time, Merck's Kenneth Frazier resigned from President Donald Trump's manufacturing council last August, just after the violence at a white supremacists' rally in Charlottesville, Virginia. Trump had insisted that the Charlottesville episode involved wrongdoing “on many ... CEO
Merck & Co. Inc. MRK, -2.33% shares dipped 1.6% in morning trade Tuesday after the company lost a patent case to Gilead Sciences Inc. GILD, +0.30% Gilead shares rose 0.4% in morning trade. The case, which involves alleged patent infringement by Gilead's hepatitis C therapy Sovaldi on a patent held ... CEO
If you're in the United States or Canada, you know it as Merck. Everywhere else, it's called MSD. Either way, it's a global pharmaceutical company with $35 billion of revenue last year. One of the roughly 70,000 employees is the CEO, Ken Frazier. He's been in the job for seven years. And he's one of the ... CEO
Forty Seven Inc., a developer of immuno-oncology treatments spun out of Stanford University, has launched a pair of collaborations with pharma giants Merck KGaA and Genentech, a member of the Roche Group, to develop its lead candidate as part of combination therapies for a trio of cancer indications. CEO
Looking at Merck & Co Inc (NYSE:MRK)'s fundamentals some investors are wondering if its last closing price of $57.6 represents a good value for money for this high growth stock. When investors want to determine if the value is still there, I usually recommend a few key checks. Let's see how MRK ... CEO
Nestle takes the lead over Mylan, Reckitt in Merck KGaA's $4B-plus OTC sale: report. by Carly Helfand |. Jan 11, 2018 10:52am. Nestle emerged as a frontrunner in the Merck KGaA consumer unit sale after Perrigo and others dropped out. (Port(u*o)s/CC BY 3.0). ShareFacebook Twitter LinkedIn Email Print. Out of several ... CEO
When it comes to pharmaceuticals, few names are as renowned as Merck & Co., Inc. (NYSE:MRK). Unfortunately in many cases, the bigger you are, the harder you fall. After a disappointing third quarter earnings report, Merck stock plummeted, leaving many question marks as to its trajectory in the new year ... CEO
I want to thank everyone for being here this afternoon and I want to thank you Chris and JPMorgan for having us. Let me start by saying we believe Merck is in a very good place right now. Coming out of last year which was a high pace and high performance year, we were able to grow notwithstanding ... CEO
Merck, along with its biopharma peers, has faced increasing price resistance since some high-profile controversies in 2015 triggered a public outcry. As the industrywide controversy continued—and politicians, including President Donald Trump, vowed to crack down on pharma—the company published a ... CEO
The CEO of big drugmaker Merck said consumers should be receiving more of the rebates being negotiated for medications. CEO Ken Frazier said he would be in favor of online retailer Amazon entering the drug distribution field if it made medication delivery more efficient. Frazier said, "I can't say I was ... CEO
San Diego's Heron Therapeutics $HRTX has won FDA approval for Cinvanti to prevent nausea and vomiting for patients on chemo. The drug ... CEO
Five years after bagging the CMV drug letermovir in a $500 million-plus deal with AiCuris, Merck says the FDA has come through with an ... CEO
Merck's revenues were driven by sales growth in its Healthcare and Life Science segment in the first half of the year. We expect the positive ... CEO
Keytruda just wasn't strong enough to overcome stiff headwinds that made Merck's third-quarter report one investors would like to forget. CEO
Several Big Pharma names have reported Q3 earnings, with volatility especially within MRK, but mostly with in line results and guidance. CEO
Merck KGaA's pharma group is taking one more step in a long journey toward rehabbing its rep in the R&D field this weekend. Company execs ... CEO
Blue chip drug makers such as Merck (NYSE:MRK) have historically been very popular with income investors because of their defensive nature ... CEO
Merck announced lung cancer trial result delays and that it was pulling its application to market key oncology drug Keytruda for lung cancer in ... CEO
Merck & Co Inc (NYSE:MRK) shares slipped lower in premarket trade after the company raised its outlook for the full year, and released a ... CEO
U.S. stock benchmarks opened mostly higher on Friday, supported by data showing the U.S. economy expanded at a solid 3% annual pace for ... CEO
Merck & Co., Inc.MRK reported third-quarter 2017 adjusted earnings of $1.11 per share, which beat the Zacks Consensus Estimate of $1.03 by ... CEO
( - Merck & Co Inc. ( MRK ) revealed a profit for its third quarter that climbed from last year. The company said its bottom line ... CEO
Merck & Co. said a cyberattack over the summer caused temporary production shutdowns and cut sales by at least $135 million in the third ... CEO
Merck reported profit ahead of Street estimates on strong sales of its cancer drug Keytruda but total revenue fell in the quarter from disruptions ... CEO
Pharmaceutical giants Merck ( MRK ) and AbbVie (ABBV) also report, along with consumer-credit reporting agency TransUnion (TRU). CEO
Merck & Co., Inc. (NYSE:MRK) market capitalization at present is $173.34B at the rate of $63.40 a share. The firm's price-to-sales ratio was ... CEO
Merck & Co. says it will slash 1,800 sales representative jobs nationwide and create a new sales team as part of a restructuring effort, the ... CEO
We expect Merck & Co., Inc.MRK to beat expectations when it reports third-quarter 2017 results on Oct 27, before market opens. Last quarter ... CEO
Chickenpox was a very common childhood illness until a Merck vaccine was introduced two decades ago; it's now part of routine childhood ... CEO
Merck is carrying out a major restructuring of its U.S. sales teams resulting in a net loss of over 800 jobs. The big pharma is ditching its primary ... CEO
Merck employs more than 12,000 in Pennsylvania, including at manufacturing and research sites in West Point and Upper Gwynedd, ... CEO


news and opinion




pharmaceutical industry:
     eli lilly